Abstract:Abstract Despite the success of adjuvant endocrine therapy in the treatment of ER+ breast cancer, recurrences occur in ~1/3 of patients with most becoming metastatic and ultimately fatal. Recurrence can be traced to drug-tolerant persister cancer cells (DTPs) that can survive years of endocrine therapy. Targeting DTPs is an attractive therapeutic approach to prevent cancer recurrence, but it has been hampered by a lack of understanding of DTP biology. We observed that subpopulations of ER+ breast cancer cells persist when challenged with estrogen deprivation and exhibit slower cell cycling, which is reversed when estrogen is restored. A CRISPR/Cas9 knock-out screen in MCF-7 DTPs identified genes that modulate fitness and survival during estrogen deprivation. Pathways analysis of the genes most essential for estrogen-independent growth revealed that mitochondrial function and oxidative phosphorylation (OXPHOS) was a top enriched pathway. Validation experiments revealed that knock-out of Mitochondrial Complex I genes conferred sensitivity to estrogen deprivation. We measured the extent of metabolic reprogramming in ER+ breast cancer cells induced by estrogen deprivation. A global proteomics study revealed widespread changes in the abundance of proteins involved in metabolism; specifically, estrogen deprivation decreased levels of glycolytic proteins while maintaining high levels of Complex I and mitoribosome proteins. Following 3 weeks of estrogen deprivation, restoration of estrogen remediated metabolic reprogramming from estrogen deprivation with higher levels of glycolysis proteins and lower mitochondrial Complex I and mitoribosome proteins. MitoTracker dye staining for mitochondria revealed increased mitochondrial content in estrogen-deprived cells, reversed by estrogen restoration in both MCF-7 and T47D DTPs. Measurement of oxygen consumption and extracellular acidification rate by Seahorse assay confirmed a shift towards greater ATP productivity by mitochondria in the setting of estrogen deprivation. The therapeutic potential of targeting mitochondrial function in DTPs was tested with the Complex I inhibitor IACS-010759. Greater drug sensitivity occurred with longer periods of estrogen deprivation in DTPs, with increased cell death at 14 and 28 days of estrogen deprivation compared to cells without previous hormone deprivation. We postulated that increased mitochondrial oxidative phosphorylation subsequently increases reactive oxygen species and oxidative stress. Indeed, DTPs exhibited an anti-oxidant stress response driven by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), a signature exhibited by ER+ tumors undergoing neoadjuvant endocrine therapy. Knock-down of NRF2 decreased survival in estrogen-deprived DTPs but not in estrogen-replete cells. The survival of NRF2-deficient DTPs was rescued by the antioxidant N-acetyl cysteine (NAC), affirming the role of an anti-oxidative stress response in preserving DTP survival. Decreased DTP survival was concomitant with an increase in ROS. These findings establish the scope of metabolic reprogramming in DTPs and offer Mitochondrial Complex I and NRF2 inhibition as novel therapeutic strategies for eradicating DTPs in ER+ breast cancer. Citation Format: Steven Tau, Todd W. Miller. Oxidative phosphorylation and NRF2 activation mediate resistance to estrogen deprivation in ER+ breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-02-12.

Abstract 1985: Ablation of adenylosuccinate lyase retarded the cell proliferation and induces mitochondrial dysfunction in endocrine therapy resistant breast cancer cells

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer

Abstract A104: ADAR1-associated metabolic vulnerabilities in triple-negative breast cancer

Abstract 431: Malic enzyme 2 inhibition reveals metabolic vulnerability in serine-dependent triple-negative breast cancer

Abstract 5935: Non-allosteric inhibition of enolase 1 sensitizes triple-negative breast cancer for checkpoint inhibitors

Abstract 563: Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer

Abstract P4-02-12: Oxidative phosphorylation and NRF2 activation mediate resistance to estrogen deprivation in ER+ breast cancer

Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer

Abstract 4758: Targeting cellular pH as a novel therapeutic strategy in CDK4/6 inhibitor resistant breast cancer

Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer

Abstract 1417: Curtailing Epithelial-Mesenchymal Plasticity for Improved Response to Breast Cancer Therapy

Abstract 3162: Genome-scale metabolic modeling suggests novel molecular targets in ER-positive breast cancer

Abstract 1222: Mechanisms of succinate-mediated drug resistance in ER+ breast cancer

Abstract 2433: Metabolic Reprogramming by an Epigenetic Mechanism in Endocrine Therapy Resistance of Breast Cancer

Abstract P1-13-13: Nuclear envelope Expression of the Oncogene Adipocyte-Associated Methionine Domain Containing Conveys Inferior Prognosis but Increased Sensitivity to Statins and Fluorouracil-Based Therapy

Abstract 3074: Regulating lactate levels in triple negative breast cancer presents a promising avenue for therapeutic intervention

Abstract 6993: SLC1A4 is associated with metabolic reprogramming in triple-negative breast cancer

Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers

Abstract 4424: Differential metabolic response of triple-negative and estrogen receptor-positive breast cancer cells to abemaciclib, a CDK4/6 inhibitor